ストックスクリーナーアプリを入手
2.23
1.83%
0.04
アフターアワーズ：
2.20
-0.03
-1.35%
前日終値:
$2.19
開ける：
$2.19
24時間の取引高:
1.07M
Relative Volume:
0.57
時価総額：
$55.54M
収益：
-
当期純損益:
$-51.50M
株価収益率:
-0.5575
EPS:
-4
ネットキャッシュフロー:
$-47.10M
1週間 パフォーマンス:
-5.91%
1か月 パフォーマンス:
+54.86%
6か月 パフォーマンス:
-75.08%
1年 パフォーマンス:
-70.13%
1日の値動き範囲:
$2.01
$2.23
1週間の範囲:
$2.01
$2.325
52週間の値動き範囲:
$0.87
$12.85
Outlook Therapeutics Inc Stock (OTLK) Company Profile
名前
Outlook Therapeutics Inc
セクター
電話
(609) 619-3990
住所
111 S. WOOD AVENUE, ISELIN, NJ
OTLK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
2.23 | 55.54M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-02 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | アップグレード | BTIG Research | Neutral → Buy |
| 2024-02-15 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-12-27 | アップグレード | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | ダウングレード | BTIG Research | Buy → Neutral |
| 2023-08-30 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | ダウングレード | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-07-13 | 開始されました | CapitalOne | Overweight |
| 2023-04-03 | 開始されました | Guggenheim | Buy |
| 2023-02-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-10-31 | 開始されました | BTIG Research | Buy |
| 2022-09-13 | 開始されました | Chardan Capital Markets | Buy |
| 2019-09-11 | 開始されました | Ladenburg Thalmann | Buy |
| 2019-05-16 | 開始されました | Oppenheimer | Outperform |
| 2019-04-22 | 開始されました | Ascendiant Capital Markets | Buy |
すべてを表示
Outlook Therapeutics Inc (OTLK) 最新ニュース
Outlook Therapeutics’ (OTLK) “Buy” Rating Reiterated at HC Wainwright - Defense World
Outlook Therapeutics (NASDAQ:OTLK) Earns Buy Rating from Guggenheim - MarketBeat
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Outlook Therapeutics (NASDAQ:OTLK) Receives Buy Rating from HC Wainwright - MarketBeat
Short Interest in Outlook Therapeutics, Inc. (NASDAQ:OTLK) Drops By 17.7% - MarketBeat
Outlook Therapeutics' (OTLK) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug - Benzinga
Outlook falls 10% on ONS-5010 update, warrant inducements - MSN
Outlook Therapeutics, Inc. Announces Complete Twelve Week Efficacy and Safety Results of Northeast EIGHT Clinical Trial - Marketscreener.com
Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial - GlobeNewswire
Outlook Therapeutics' ONS-5010 Matches Ranibizumab in 12-Week AMD Trial Results - StockTitan
Analysts Set Outlook Therapeutics, Inc. (NASDAQ:OTLK) Price Target at $32.73 - Defense World
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Outlook Therapeutics Reports 2024 Financial Results - MSN
Barclays PLC Increases Position in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Geode Capital Management LLC Raises Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
OTLKOutlook Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Outlook Therapeutics® Participates in Virtual Investor "What This Means” Segment - The Manila Times
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment - GlobeNewswire
Outlook's LYTENAVA Makes History: First Approved Ophthalmic Bevacizumab for Wet AMD in UK - StockTitan
Spartan Delta Corp (SDE-T) QuotePress Release - The Globe and Mail
Outlook Therapeutics (NASDAQ:OTLK) versus Candel Therapeutics (NASDAQ:CADL) Financial Survey - Defense World
State Street Corp Buys 21,201 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Analysts Offer Predictions for OTLK Q1 Earnings - Defense World
OTLK FY2026 EPS Lifted by Brookline Capital Management - Defense World
Age-related Vision Dysfunction Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Treatment, Companies by DelveInsight - The Globe and Mail
Biotech Alert: Searches spiking for these stocks today - TipRanks
Outlook Therapeutics Stock Surges on Positive Outlook Despite Lo - GuruFocus.com
Outlook Therapeutics Stock Surges on Positive Outlook Despite Loss - Yahoo Finance
Outlook Therapeutics Faces Business Risks from Third-Party Manufacturing Dependencies - MSN
Outlook Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - Marketscreener.com
Outlook Therapeutics provides ONS-5010/LYTENAVA update - Yahoo Finance
Outlook Therapeutics Inc. (OTLK) reports earnings - Quartz
Outlook Therapeutics Shares Up, Outlines Plans for Macular Degeneration Treatment - Marketscreener.com
Outlook Therapeutics Inc Reports Fiscal Year 2024 EPS of -$4.06, Missing Revenue Estimate of $0.24 Million - GuruFocus.com
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update - The Manila Times
Outlook Therapeutics Secures EU Approval for LYTENAVA™, First Bevacizumab Eye Treatment for Wet AMD - StockTitan
Brokerages Set Outlook Therapeutics, Inc. (NASDAQ:OTLK) PT at $42.34 - Defense World
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutic - GuruFocus.com
Charles Schwab Investment Management Inc. Grows Stock Position in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Outlook Therapeutics : Reorganization Form 8 K - Marketscreener.com
Outlook Therapeutics® Streamlines Operations - The Manila Times
Outlook Therapeutics, Inc. Streamlines Operations - Marketscreener.com
Outlook Therapeutics to Cut 23% of Workforce in Push for Lytenava Commercial Launch - MarketWatch
After Golden Cross, Xilio Therapeutics, Inc. (XLO)'s Technical Outlook is Bright - Yahoo Finance
Outlook nabs NICE nod in wet AMD - The Pharma Letter
Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD - The Manila Times
Outlook Therapeutics® Announces NICE Recommendation of - GlobeNewswire
Outlook Therapeutics' LYTENAVA Secures Groundbreaking NICE Recommendation for Wet AMD Treatment | OTLKW Stock News - StockTitan
Outlook Therapeutics Inc (OTLK) 財務データ
収益
当期純利益
現金流量
EPS
Outlook Therapeutics Inc (OTLK) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Haddadin Yezan Munther | Director |
Mar 28 '24 |
Buy |
11.82 |
1,882 |
22,242 |
5,049 |
| Evanson Jeff | CHIEF COMMERCIAL OFFICER |
Mar 07 '24 |
Buy |
0.42 |
62,484 |
26,243 |
808,459 |
0.65%
4.62%
大文字化:
|
ボリューム (24 時間):